Clinical trials
Non-Alcoholic Fatty Liver Disease clinical trials
Below are recruiting non-alcoholic fatty liver disease clinical trials, each written for real people, not researchers. We’re tracking 102 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06717828Recruiting
Tai Chi for fatty liver in older adults
This trial tests whether Tai Chi, a gentle exercise, can improve fatty liver disease in middle-aged and older adults who are overweight. If you are between 40 and 75 and have metabolic fatty liver, you might be able to join.
Fuzhou, FujianAges 40–75 - NCT07564947Enrolling by invitation
Reishi Mushroom for Fatty Liver Disease
This study tests whether Ganoderma lucidum (reishi mushroom) can improve liver health and reduce inflammation in people with fatty liver disease. Researchers will measure how it affects your liver function and antioxidant levels.
Peshawar, Khyber PakhtunkhwaAges 35–49 - NCT06735118Recruiting
Can AI help see chemo-related fatty liver?
This study uses a special MRI technique and artificial intelligence to see how chemotherapy may cause a fatty liver. It may help find liver changes early in people who have had chemo.
Kunming, YunnanAges 18–80 - NCT07553663RecruitingPhase 1
Testing a new liver disease treatment for fatty liver
This study tests how your body processes a new medication called miricorilant, designed to help people with fatty liver disease (MASH). You'll have liver scans or recent biopsy results and metabolic conditions like diabetes or high blood pressure.
San Antonio, TexasAges 18–75 - NCT06694935RecruitingPhase 1
Testing QX1206 in type 2 diabetes with fatty liver
This trial tests a new pill called QX1206 for people who have both Type 2 diabetes and fatty liver disease (NAFLD). The goal is to see if the medicine is safe and can help improve both conditions.
TorontoAges 18–64 - NCT07452744Enrolling by invitation
Picroliv for non-alcoholic fatty liver disease
This study tests a plant-based medicine called Picroliv for people with non-alcoholic fatty liver disease (NAFLD). It aims to see if it is safe and can reduce fat in the liver.
Chandigarh, ChandigarhAges 18–60 - NCT06803108Recruiting
Pyramidal vs continuous exercise for fatty liver
This study compares two exercise programs to see which works better for people with fatty liver disease and obesity. It may help improve liver health through different workout styles.
GizaAges 37–51 - NCT06814600Recruiting
Fatty liver study in inflammatory bowel disease patients
This study checks how often people with Crohn's or ulcerative colitis also have fatty liver disease. It uses a painless scan to measure liver stiffness and fat. If you have IBD, you may join to help researchers learn about the link between these conditions.
BrusselsAges 18 years+ - NCT03875625Recruiting
Tracking body fat and liver fat after weight-loss treatment
This study looks at how body fat and liver fat change after bariatric (weight-loss) surgery or a lifestyle program. You may join if you have overweight or obesity and can safely have MRI scans, so researchers can compare results between treatment approaches.
Hong Kong, ShatinAges 18–65 - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65 - NCT07376486Recruiting
Early treatment for type 2 diabetes using a new duodenal procedure
This study tests a new procedure called pulsENDO, which is done in the first part of the small intestine (the duodenum) to help treat type 2 diabetes. It may be an option for people who were recently diagnosed and have good blood sugar control with little or no diabetes medication.
ShatinAges 18–60 - NCT07358546RecruitingPhase 1
Test of efimosfermin alfa in adults with liver problems
This trial is for adults with liver cirrhosis (scarring) who have moderate to severe liver impairment. It studies how the body handles a new medicine called efimosfermin alfa, to see if it could be a safe treatment option. You may be able to join if your liver function is stable and you fall into a specific Child-Pugh class.
Rialto, CaliforniaAges 18–70 - NCT03535142Recruiting
Fatty liver in people considering bariatric surgery
This study looks at how fatty liver disease may predict future liver health in people with severe weight gain. It compares people who are planning bariatric (weight-loss) surgery with similar people who are not, to better understand who may be at higher risk.
EsbjergAges 18 years+ - NCT07330830Recruiting
Genetics and fatty liver disease in Caribbean and Indian Ocean populations
This study looks at how a specific gene (PNPLA3) might affect non-alcoholic fatty liver disease (MASLD) in people from Guadeloupe, French Guiana, and Réunion Island. It aims to understand genetic differences that could explain why some people get the disease.
CayenneAges 18 years+ - NCT04807868Recruiting
Liver fat registry for adults with or at risk for fatty liver
This study builds a research registry (and optional test results follow-up) for adults who either need a routine liver biopsy or may have fatty liver risk based on body weight and other health history. It helps researchers learn more about non-alcoholic fatty liver disease (fatty liver not caused by alcohol) and how it may progress.
Orlando, FloridaAges 18 years+ - NCT07308548RecruitingPhase 2
Testing HP515 for fatty liver disease (NASH/MASH)
This trial tests a new drug called HP515 for people with non-alcoholic fatty liver disease, including NASH or MASH. It aims to see if the drug can help reduce liver fat and improve liver health.
Beijing, Beijing MunicipalityAges 18–65 - NCT06890169Recruiting
One-stop telehealth program for weight and diabetes
This trial tests a telehealth program that helps people lose weight and manage type 2 diabetes and fatty liver disease at the same time. It's a one-stop remote clinic that combines medical advice, nutrition, and lifestyle support.
SingaporeAges 21–70 - NCT07270601Recruiting
Ultrasound test for liver fat
This study is testing a new ultrasound method to measure fat in the liver. It is for people who may have a liver condition or have risk factors like diabetes or obesity, as well as healthy volunteers.
Seattle, WashingtonAges 18–75 - NCT07265544Recruiting
Liver disease study using advanced tissue analysis
This study uses advanced techniques to analyze liver tissue samples from people with various liver conditions. It aims to better understand how liver diseases develop and progress, which may help improve future treatments.
Guangzhou, GuangdongAges Any age - NCT07241195Recruiting
Fatty Liver Study in Older Adults
This study follows older adults with fatty liver disease to understand how their metabolism changes over time and how it affects their overall health. It helps researchers learn more about the condition and its impact on the body outside the liver.
Hangzhou, ZhejiangAges 65–100 - NCT07221227RecruitingPhase 3
Testing a new drug for MASH with moderate scarring
This trial tests a new medicine called Efimosfermin Alfa for people with MASH (a fatty liver disease) and moderate liver scarring. It aims to see if the medicine can improve the liver condition.
Chandler, ArizonaAges 18–75 - NCT07221188RecruitingPhase 3
Efimosfermin alfa for liver scarring in MASH
This study tests an investigational drug called efimosfermin alfa to see if it is safe and tolerable for people who have liver scarring (F2 or F3 stage) from a condition called MASH. The goal is to find out if the drug can help without causing serious side effects.
Arcadia, CaliforniaAges 18–75 - NCT06939569Recruiting
Studying fatty liver disease in people with inflammatory bowel disease
This study looks at how common non-alcoholic fatty liver disease is in people with inflammatory bowel disease (Crohn's or colitis). Researchers want to learn more about the link between the two conditions.
ShanghaiAges 18 years+ - NCT07128797RecruitingPhase 1
Safety and tolerability of B1344 injections for NAFLD
This trial tests whether multiple injections of B1344 are safe and tolerable in people with nonalcoholic fatty liver disease (NAFLD). It aims to find the right dose and check how the drug works in the body.
Beijing, Beijing MunicipalityAges 18–75
Hear when a new Non-Alcoholic Fatty Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for non-alcoholic fatty liver disease?
- Yes. Clin2 currently lists 102 recruiting non-alcoholic fatty liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a non-alcoholic fatty liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a non-alcoholic fatty liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.